Previous Close | 2.4 |
1-Year Change | -23.57% |
6-Months Change | 2.56% |
3-Months Change | 10.6% |
Moving Avg (50d) | 2.362 |
Moving Avg (200d) | 2.3734 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 96.7M |
Beta (3-Years) | 1.31 |
Revenue Growth (ttm) | -16.77% |
Net Profit Margin (ttm) | -728.79% |
Return On Assets (ttm) | -7.08% |
EPS (ttm) | 0.28 |
PE Ratio (ttm) | 8.57 |
Dividend Yield | % |
Asset Description: | Oramed Pharmaceuticals Inc. |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2025-01-08 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
2.448 | 2.52 | 2.568 | 2.64 | 2.76 | 2.88 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |